John Danhakl, a director at IQVIA Holdings (IQV), recently started a stake at the company with 63,451 shares. The total cost of the buy came to just over $11.2 million.
This marks the first buy from a company insider since August. Over the past three years, company insiders have largely been sellers. In 2020, those sales have largely been by major owners and directors, rather than C-suite executives.
The healthcare life sciences and diagnostics company has seen shares move about in-line with the stock market over the past year, with a gain of about 15 percent. Its revenues have been flat, and its profit margins are a scanty 1.6 percent.
- New “Forever Battery” To Usher In New Age Of Energy
The breakthrough battery technology being dubbed as “The Tesla Killer”.
Find out why you need to act now to take advantage of this incredible opportunity.
Tech investing legend Matt McCall reveals a secretly emerging $3 trillion industry HERE.
Action to take: Even with this large buy, insiders have largely been sellers, and insiders own less than 1 percent of shares. The stock is in a general uptrend, which looks like the best reason to make a trade over a factor like insider activity.
For traders, the May 2021 $175 calls are an at-the-money trade. Last going for about $14.50, they offer traders a mid-to-high double-digit returns. They have plenty of time for the gradual uptrend to play out, but traders should be on the lookout to close the trade early if shares start to lose their current uptrend.